Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019
Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) or Death receptor 5 (DR5) is a protein encoded by TNFRSF10B. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 5, 11, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Hematological Disorders, Immunology and Respiratory which include indications Colorectal Cancer, Solid Tumor, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Colon Carcinoma, Diffuse Large B-Cell Lymphoma, Esophageal Cancer, Gastrointestinal Tract Cancer, Glioma, Hematological Tumor, Liver Cancer, Liver Cirrhosis, Liver Fibrosis, Lung Cancer, Malignant Ascites, Malignant Glioma, Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Pancreatitis, Peritoneal Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sarcomas, Systemic Sclerosis (Scleroderma), T-Cell Leukemia and Transitional Cell Cancer (Urothelial Cell Cancer).
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) or Death receptor 5 (DR5) is a protein encoded by TNFRSF10B. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 5, 11, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Hematological Disorders, Immunology and Respiratory which include indications Colorectal Cancer, Solid Tumor, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Colon Carcinoma, Diffuse Large B-Cell Lymphoma, Esophageal Cancer, Gastrointestinal Tract Cancer, Glioma, Hematological Tumor, Liver Cancer, Liver Cirrhosis, Liver Fibrosis, Lung Cancer, Malignant Ascites, Malignant Glioma, Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Pancreatitis, Peritoneal Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sarcomas, Systemic Sclerosis (Scleroderma), T-Cell Leukemia and Transitional Cell Cancer (Urothelial Cell Cancer).
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Companies Involved in Therapeutics Development
AbbVie Inc
Apollo Therapeutics LLC
AstraZeneca Plc
Beijing Sinotau Pharmaceutical Technology Co Ltd
Beijing Sunbio Biotech Co Ltd
Biomirex Inc
Boehringer Ingelheim International GmbH
Chengdu Huachuang Biotechnology Co Ltd
Clover Biopharmaceuticals
D&D Pharmatech Co Ltd
Daiichi Sankyo Co Ltd
Galaxy Biotech LLC
Genmab A/S
i2 Pharmaceuticals Inc
IGM Biosciences Inc
Inhibrx Inc
JN Biosciences LLC
MacroGenics Inc
Neonc Technologies Inc
Obio Technology (Shanghai) Corp Ltd
Polaris Pharmaceuticals Inc
Shanghai Gebaide Biotechnology Co Ltd
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Drug Profiles
ABBV-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-905711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Antibody to Agonize EPHB6 and DR5 for Triple-Negative Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD19L-sTRAIL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTB-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-8273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dulanermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize TRAIL Receptor-2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEN-1029 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuG-4.2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuGOH-729S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INBRX-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-3039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize DR5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize DR5 for Hematological Tumor and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize TRAILR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-30000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize TNFRSF10A, TNFRSF10B, TNFRSF10C and TNFRSF10D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize DR4 and DR5 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLY-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites
Sep 24, 2019: Theraly Fibrosis granted US Orphan Drug Designation for TLY012 for chronic pancreatitis
Sep 10, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Peritoneal Carcinomatosis
Sep 03, 2019: Inhibrx reports phase 1 dose escalation results of INBRX-109, a multivalent agonist of death receptor 5
May 30, 2019: AbbVie presents update on ABBV-621 at the 2019 ASCO
May 07, 2019: Clover Biopharmaceuticals receives NMPA approval for SCB-313 (TRAIL-Trimer) to initiate clinical trials in China
Dec 06, 2018: Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)
Dec 04, 2018: iDD biotech receives second milestone payment from Genmab with enrolment of fifth patient in Gen1029 safety trial
Jun 18, 2018: Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
Nov 21, 2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition
Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Companies Involved in Therapeutics Development
AbbVie Inc
Apollo Therapeutics LLC
AstraZeneca Plc
Beijing Sinotau Pharmaceutical Technology Co Ltd
Beijing Sunbio Biotech Co Ltd
Biomirex Inc
Boehringer Ingelheim International GmbH
Chengdu Huachuang Biotechnology Co Ltd
Clover Biopharmaceuticals
D&D Pharmatech Co Ltd
Daiichi Sankyo Co Ltd
Galaxy Biotech LLC
Genmab A/S
i2 Pharmaceuticals Inc
IGM Biosciences Inc
Inhibrx Inc
JN Biosciences LLC
MacroGenics Inc
Neonc Technologies Inc
Obio Technology (Shanghai) Corp Ltd
Polaris Pharmaceuticals Inc
Shanghai Gebaide Biotechnology Co Ltd
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Drug Profiles
ABBV-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-905711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Antibody to Agonize EPHB6 and DR5 for Triple-Negative Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD19L-sTRAIL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTB-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-8273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dulanermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize TRAIL Receptor-2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEN-1029 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuG-4.2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuGOH-729S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INBRX-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-3039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize DR5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize DR5 for Hematological Tumor and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize TRAILR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-30000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize TNFRSF10A, TNFRSF10B, TNFRSF10C and TNFRSF10D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize DR4 and DR5 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLY-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites
Sep 24, 2019: Theraly Fibrosis granted US Orphan Drug Designation for TLY012 for chronic pancreatitis
Sep 10, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Peritoneal Carcinomatosis
Sep 03, 2019: Inhibrx reports phase 1 dose escalation results of INBRX-109, a multivalent agonist of death receptor 5
May 30, 2019: AbbVie presents update on ABBV-621 at the 2019 ASCO
May 07, 2019: Clover Biopharmaceuticals receives NMPA approval for SCB-313 (TRAIL-Trimer) to initiate clinical trials in China
Dec 06, 2018: Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)
Dec 04, 2018: iDD biotech receives second milestone payment from Genmab with enrolment of fifth patient in Gen1029 safety trial
Jun 18, 2018: Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
Nov 21, 2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition
Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Apollo Therapeutics LLC, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Beijing Sinotau Pharmaceutical Technology Co Ltd, H2 2019
Pipeline by Beijing Sunbio Biotech Co Ltd, H2 2019
Pipeline by Biomirex Inc, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Chengdu Huachuang Biotechnology Co Ltd, H2 2019
Pipeline by Clover Biopharmaceuticals, H2 2019
Pipeline by D&D Pharmatech Co Ltd, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Galaxy Biotech LLC, H2 2019
Pipeline by Genmab A/S, H2 2019
Pipeline by i2 Pharmaceuticals Inc, H2 2019
Pipeline by IGM Biosciences Inc, H2 2019
Pipeline by Inhibrx Inc, H2 2019
Pipeline by JN Biosciences LLC, H2 2019
Pipeline by MacroGenics Inc, H2 2019
Pipeline by Neonc Technologies Inc, H2 2019
Pipeline by Obio Technology (Shanghai) Corp Ltd, H2 2019
Pipeline by Polaris Pharmaceuticals Inc, H2 2019
Pipeline by Shanghai Gebaide Biotechnology Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Apollo Therapeutics LLC, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Beijing Sinotau Pharmaceutical Technology Co Ltd, H2 2019
Pipeline by Beijing Sunbio Biotech Co Ltd, H2 2019
Pipeline by Biomirex Inc, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Chengdu Huachuang Biotechnology Co Ltd, H2 2019
Pipeline by Clover Biopharmaceuticals, H2 2019
Pipeline by D&D Pharmatech Co Ltd, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Galaxy Biotech LLC, H2 2019
Pipeline by Genmab A/S, H2 2019
Pipeline by i2 Pharmaceuticals Inc, H2 2019
Pipeline by IGM Biosciences Inc, H2 2019
Pipeline by Inhibrx Inc, H2 2019
Pipeline by JN Biosciences LLC, H2 2019
Pipeline by MacroGenics Inc, H2 2019
Pipeline by Neonc Technologies Inc, H2 2019
Pipeline by Obio Technology (Shanghai) Corp Ltd, H2 2019
Pipeline by Polaris Pharmaceuticals Inc, H2 2019
Pipeline by Shanghai Gebaide Biotechnology Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Apollo Therapeutics LLC
AstraZeneca Plc
Beijing Sinotau Pharmaceutical Technology Co Ltd
Beijing Sunbio Biotech Co Ltd
Biomirex Inc
Boehringer Ingelheim International GmbH
Chengdu Huachuang Biotechnology Co Ltd
Clover Biopharmaceuticals
D&D Pharmatech Co Ltd
Daiichi Sankyo Co Ltd
Galaxy Biotech LLC
Genmab A/S
i2 Pharmaceuticals Inc
IGM Biosciences Inc
Inhibrx Inc
JN Biosciences LLC
MacroGenics Inc
Neonc Technologies Inc
Obio Technology (Shanghai) Corp Ltd
Polaris Pharmaceuticals Inc
Shanghai Gebaide Biotechnology Co Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Apollo Therapeutics LLC
AstraZeneca Plc
Beijing Sinotau Pharmaceutical Technology Co Ltd
Beijing Sunbio Biotech Co Ltd
Biomirex Inc
Boehringer Ingelheim International GmbH
Chengdu Huachuang Biotechnology Co Ltd
Clover Biopharmaceuticals
D&D Pharmatech Co Ltd
Daiichi Sankyo Co Ltd
Galaxy Biotech LLC
Genmab A/S
i2 Pharmaceuticals Inc
IGM Biosciences Inc
Inhibrx Inc
JN Biosciences LLC
MacroGenics Inc
Neonc Technologies Inc
Obio Technology (Shanghai) Corp Ltd
Polaris Pharmaceuticals Inc
Shanghai Gebaide Biotechnology Co Ltd
